Lapatinib plus capecitabine showed greater efficacy than capecitabine alone in patients with HER2-positive breast cancer who had previously been treated with at least one anthracycline, one taxane, and trastuzumab [62]. This evidence concerns the gene ERBB2 and breast cancer.